假体周围真菌感染中,由念珠菌引起的模块化内假体假体关节感染的治疗失败率和截肢率较高
本研究回顾性分析2000年至2022年间86例接受大假体植入后发生假体关节感染(PJI)的患者,纳入10例真菌性大假体PJI患者。最常见病原体为白色念珠菌(5/10)和近平滑念珠菌(3/10),6/10例合并细菌感染。1年无再手术生存率35%、无翻修生存率42%,2年分别降至12%和14%;1年无截肢生存率74%,2年降至40%。作者认为真菌性大假体PJI罕见但破坏性大,未来需多机构合作扩大样本。
要点
- 真菌性大假体PJI最常见病原体为白色念珠菌(5/10)和近平滑念珠菌(3/10),6/10例合并细菌感染。
- 1年无再手术生存率35%(95%CI 9%–64%),2年降至12%(95%CI 1%–40%)。
- 1年无截肢生存率74%(95%CI 30%–93%),2年降至40%(95%CI 7%–73%)。
核心结论
- 大假体真菌性PJI罕见但具有破坏性,作者认为关节置换外科医生应考虑不同手术策略似乎均较低的治疗效力以及患者承受该治疗的能力。
- 作者认为,对于需要快速控制感染以启动免疫抑制治疗的患者,可考虑降低实施截肢的决策阈值。
- 作者提出未来研究应旨在控制潜在变量后比较真菌性PJI与其他病因PJI的手术和临床结局,并应努力建立多机构合作以获得更大研究样本。
研究设计与样本
- 回顾性分析本机构数据库中2000年至2022年间86例大假体植入后诊断为PJI并接受手术治疗的患者。
- 纳入微生物培养真菌阳性且自PJI初始治疗起最低随访2年的患者,共10例;4例随访短于2年但均在较早 interval 达到研究终点而纳入。
- 所有纳入患者均在2016年至2022年间治疗,PJI诊断依据2011年肌肉骨骼感染学会标准。
- 治疗方案包括清创、抗生素和假体保留(DAIR),DAIR-plus(清创、抗生素、模块化假体组件更换和柄保留),或一期或二期翻修。
- 采用Kaplan-Meier生存分析计算自PJI指数手术起1年和2年的无再手术、无翻修和无截肢生存率。
主要发现
- 最常见微生物为白色念珠菌(5/10)和近平滑念珠菌(3/10),6/10例合并细菌感染。
- 1年无再手术生存率为35%(95%CI 9%至64%),无翻修生存率为42%(95%CI 11%至71%)。
- 2年无再手术生存率为12%(95%CI 1%至40%),无翻修生存率为14%(95%CI 1%至46%)。
- 1年无截肢生存率为74%(95%CI 30%至93%),2年无截肢生存率为40%(95%CI 7%至73%)。
- 末次随访时,4例患者已接受截肢,4例正在接受慢性抗真菌抑制治疗。
关键数值与推荐
- PJI诊断依据2011年肌肉骨骼感染学会标准。
- 纳入标准为微生物培养真菌阳性且自PJI初始治疗起最低随访2年。
- 1年无再手术生存率35%(95%CI 9%至64%),无翻修生存率42%(95%CI 11%至71%)。
- 2年无再手术生存率12%(95%CI 1%至40%),无翻修生存率14%(95%CI 1%至46%)。
- 1年无截肢生存率74%(95%CI 30%至93%),2年无截肢生存率40%(95%CI 7%至73%)。
临床怎么用
- 作者认为关节置换外科医生应考虑不同手术策略似乎均较低的治疗效力以及患者承受该治疗的能力。
- 作者认为对于需要快速控制感染以启动免疫抑制治疗的患者,可考虑降低实施截肢的决策阈值。
局限性
- 原文为回顾性分析。
- 样本量小(10例)。
- 4例患者随访短于2年。
- 作者提出未来研究应控制潜在变量后比较真菌性PJI与其他病因PJI的手术和临床结局。
- 作者提出应努力建立多机构合作以获得更大研究样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fungal prosthetic joint infections (PJIs) are rare yet severe events associated with high rates of recurrent infection. Although bacterial PJIs associated with megaprostheses are known to be associated with higher rates of recurrence and amputation, little is known about fungal PJIs near megaprostheses. QUESTIONS/PURPOSES: In patients with fungal megaprosthesis PJIs from one institutional registry, we asked: (1) What were the most common microorganisms isolated? (2) What were the reoperation-, revision-, and amputation-free survival rates 1 and 2 years after surgery? METHODS: We conducted a retrospective analysis of megaprostheses in our institutional database. Between 2000 and 2022, 86 patients with a diagnosis of PJI after megaprosthesis implantation were surgically treated at our institution. We considered patients with microbiological cultures that were positive for fungal organisms and who had a minimum follow-up of 2 years from the initial treatment for PJI. Ten patients with fungal megaprosthesis PJIs were included. Although four patients had a follow-up shorter than 2 years, all reached one of the study endpoints at that earlier interval, and therefore were included. All included patients were treated between 2016 and 2022, and the diagnosis of PJI was made in accordance with the 2011 Musculoskeletal Infection Society criteria. Patients were treated with either debridement, antibiotics, and implant retention (DAIR), DAIR-plus (debridement, antibiotics, modular implant component exchange, and stem retention), or one-stage or two-stage revision. In general, DAIR was used for acute PJIs, while DAIR-plus was performed in patients with chronic PJIs who were deemed medically unfit to endure the high morbidity associated with removal of the stems. In cases of prior unsuccessful DAIR-plus or patients with fewer comorbidities, one-stage or two-stage revision was the main treatment approach. The median age at diagnosis was 67 years (range 32 to 84 years), 5 of 10 patients were female, and the median BMI was 31 kg/m 2 (range 20 to 43 kg/m 2 ). The median follow-up was 26 months (range 1 to 54 months). A Kaplan-Meier survival analysis was performed to calculate reoperation-, revision-, and amputation-free survival at 1 and 2 years from the index surgery for PJI. RESULTS: The two most common organisms were Candida albicans (5 of 10 patients) and C.parapsilosis (3 of 10). Six of 10 patients had coinfection with a bacterial organism. One-year reoperation-free and revision-free survival were 35% (95% CI 9% to 64%) and 42% (95% CI 11% to 71%), respectively. Two-year reoperation-free and revision-free survival were 12% (95% CI 1% to 40%) and 14% (95% CI 1% to 46%), respectively. Amputation-free survival was 74% (95% CI 30% to 93%) at the 1-year interval and 40% at the 2-year interval (95% CI 7% to 73%). At the final follow-up interval, four patients had undergone amputations and four were being administered chronic antifungal suppression. CONCLUSION: Megaprosthesis fungal PJIs are rare but devastating. Arthroplasty surgeons should consider treatment efficacy, which appears to be low across surgical strategies, and the patient's capacity to withstand it. A lower decision threshold for performing amputation may be considered in patients who require rapid infection control to initiate immunosuppressive treatments. Future studies should aim to compare the surgical and clinical outcomes of fungal PJIs with those of other etiologies while controlling for potential variables. Efforts should be made to establish multi-institutional collaborations to achieve larger study samples. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Gonzalez MR, Clunk MJ, Acosta JI, et al. High Rates of Treatment Failure and Amputation in Modular Endoprosthesis Prosthetic Joint Infections Caused by Fungal Infections With Candida. Clin Orthop Relat Res. 2023. PMID: 37988003. doi:10.1097/CORR.0000000000002918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。